This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock
by Zacks Equity Research
Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.
Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 150.4% upside potential for Valneva (VALN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3%
by Zacks Equity Research
The consensus price target hints at a 135.3% upside potential for Valneva (VALN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Valneva (VALN) Climb 149.04% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 149% upside potential for Valneva (VALN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine
by Zacks Equity Research
Valneva (VALN) gets European Commission???s marketing authorization in Europe for Valneva???s single-dose Chikungunya vaccine, IXCHIQ. The company is set to launch IXCHIQ in Europe in late 2024.
Valneva's (VALN) CHIKV Vaccine Gets Health Canada's Approval
by Zacks Equity Research
Valneva's (VALN) IXCHIQ, the world's only licensed chikungunya vaccine, is a critical tool in combating this public health threat.
Strength Seen in Valneva SE Sponsored ADR (VALN): Can Its 15.8% Jump Turn into More Strength?
by Zacks Equity Research
Valneva SE Sponsored ADR (VALN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why
by Zacks Equity Research
The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.
Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why
by Zacks Equity Research
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.
What Makes Valneva SE Sponsored ADR (VALN) a New Buy Stock
by Zacks Equity Research
Valneva SE Sponsored ADR (VALN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab
by Zacks Equity Research
Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.
Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data
by Zacks Equity Research
Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.
Wall Street Analysts See a 65% Upside in Valneva SE Sponsored ADR (VALN): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Valneva SE Sponsored ADR (VALN) points to a 65.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
All You Need to Know About Valneva SE Sponsored ADR (VALN) Rating Upgrade to Buy
by Zacks Equity Research
Valneva SE Sponsored ADR (VALN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why
by Zacks Equity Research
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.
Valneva SE Sponsored ADR (VALN) Stock Jumps 93.1%: Will It Continue to Soar?
by Zacks Equity Research
Valneva SE Sponsored ADR (VALN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Pfizer (PFE) to Buy 8.1% Stake in Lyme Disease Vaccine Partner
by Zacks Equity Research
Pfizer (PFE) is set to acquire 8.1% stake in Valneva's stock. Valneva will use the cash from this investment to support its phase III study for VLA15.
Valneva (VALN) Stock Declines 59% in 3 Months: Here's Why
by Zacks Equity Research
Though Valneva's (VALN) COVID-19 vaccine looks promising, the European Commission's intent to terminate the advance purchase agreement for the vaccine puts the future of the company's COVID-19 vaccine program into jeopardy.
Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More
by Zacks Equity Research
Regulatory and other updates from bluebird (BLUE) and Rigel (RIGL) are a few key highlights from the biotech sector during the past week.
Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe
by Zacks Equity Research
Valneva (VALN) slides on a proposed remediation plan update after receiving the European Commission's notice of intent to terminate the Advance Purchase Agreement for its COVID-19 vaccine.
Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA
by Zacks Equity Research
Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.
Valneva (VALN) Down as EU Considers Ending COVID-Vaccine Deal
by Zacks Equity Research
Per the agreement with the European Commission, Valneva (VALN) has 30 days from May 13, 2022 to win a marketing authorization in the EU for its COVID vaccine or offer an acceptable remediation plan.
Valneva (VALN) Completes Phase III Chikungunya Vaccine Study
by Zacks Equity Research
Valneva's (VALN) phase III study evaluating its chikungunya vaccine achieves all primary and secondary endpoints. The stock rises 9.2% following the announcement.
Will Dynavax's (DVAX) Growth Momentum Continue in 2022?
by Zacks Equity Research
Year-over-year revenue growth for HEPLISAV-B and CpG 1018 adjuvant is expected to drive Dynavax???s (DVAX) profitability in 2022.
Valneva (VALN) Up as COVID-19 Jab Neutralizes Omicron Variant
by Zacks Equity Research
Three doses of Valneva's (VALN) inactivated COVID-19 vaccine candidate, VLA2001, neutralizes the Omicron variant of SARS-CoV-2, per data from preliminary lab studies. Shares rally.